MGO One Seven LLC Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

MGO One Seven LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 13.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 20,066 shares of the company’s stock after acquiring an additional 2,413 shares during the quarter. MGO One Seven LLC’s holdings in Novo Nordisk A/S were worth $1,726,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of NVO. Center for Financial Planning Inc. raised its position in shares of Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL increased its stake in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after buying an additional 300 shares during the last quarter. Transce3nd LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $33,000. Kelly Lawrence W & Associates Inc. CA bought a new position in Novo Nordisk A/S during the 4th quarter valued at $39,000. Finally, Albion Financial Group UT grew its holdings in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Dbs Bank downgraded shares of Novo Nordisk A/S to a “sell” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $135.00.

Novo Nordisk A/S Stock Up 2.1 %

NVO stock opened at $62.59 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm’s 50-day simple moving average is $74.03 and its 200 day simple moving average is $90.18. The stock has a market cap of $280.87 billion, a PE ratio of 19.02, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.